(Boursier.com) — Johnson & Johnson, the American giant of the pharmaceutical and medical industry, and until recently of hygiene or cosmetic products, which benefits from the strong demand for its cancer treatments Carvykti and Tecvayli, today raised its financial forecasts for financial year 2023. The group is therefore counting on adjusted earnings per share for 2023 ranging from $10.07 to $10.13, compared to $10 to $10.10 previously. Operating revenues for the year are now expected to be between $84.4 and $84.8 billion, representing growth of 8.7% in the middle of the range versus 8% previously estimated.
For the third fiscal quarter, J&J posted earnings per share of $1.69 per share compared to $1.62 a year before, and adjusted EPS of $2.66, an increase of 19%. Third-quarter revenues rose 6.8% to $21.4 billion, with operational growth of 6.4% – and even 9% excluding the Covid-19 vaccine. Quarterly net profit was $4.31 billion, almost flat year-on-year.
©2023 Boursier.com